We join Kohei Shitara at ESMO 2019 to discuss the future of immuno-oncology in gastric/gastroesophageal junction cancer.
Questions
1. What are the major challenges of immuno-oncology (I-O) in gastric/gastroesophageal junction cancer? (0:05)
2. Which I-O approaches look most promising, to date? (0:45)
3. What are the most promising biomarkers of response to immune checkpoint inhibitors in this treatment setting? (1:46)
4. What are the potential challenges and benefits of combined treatment approaches with immune checkpoint inhibitors? (2:34)
5. In what other ways do you expect I-O to evolve in this treatment setting? (3:56)
Kohei Shitara has acted as a consultant/advisor for, and received research funding from, MSD.
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
